Biotech · Private company
Axcella Health, Inc
Track this companyFree. Adds Axcella Health, Inc to your Dealase workspace and tells you when its record changes.
Clinical trials50 recruiting or active
Pipeline programs6From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline6
- AXA1125Phase 2 · Non Alcoholic Steatohepatitis (NASH)ClinicalTrials.gov · fetched Nov 12, 2026
- AXA1665Phase 2 · Hepatic EncephalopathyClinicalTrials.gov · fetched Nov 12, 2026
- AXA1125NAFLDClinicalTrials.gov · fetched Nov 12, 2026
- AXA1665Hepatic InsufficiencyClinicalTrials.gov · fetched Nov 12, 2026
- AXA1957NAFLDClinicalTrials.gov · fetched Nov 12, 2026
- AXA4010To Assess the Safety and Tolerabiltiy of an Amino Acid Composition in Subjects With Sickle Cell DiseaseClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials5
- Efficacy and Safety of AXA1665 in Cirrhotic Subjects With Prior Overt Hepatic EncephalopathyPHASE2 · TERMINATED · started Jun 29, 2021ClinicalTrials.gov NCT04816916 · fetched Nov 12, 2026
- Safety, Tolerability, and Efficacy of AXA1125 in NASH With FibrosisPHASE2 · UNKNOWN · started May 7, 2021ClinicalTrials.gov NCT04880187 · fetched Nov 12, 2026
- To Assess Safety, Tolerability and Physiological Effects on Structure and Function of AXA4010 in Subjects With Sickle Cell DiseaseNA · COMPLETED · started Sep 25, 2019ClinicalTrials.gov NCT04134299 · fetched Nov 12, 2026
- Study of the Safety and Tolerability of AXA1665 in Subjects With Mild and Moderate Hepatic InsufficiencyNA · COMPLETED · started Mar 30, 2019ClinicalTrials.gov NCT04147936 · fetched Nov 12, 2026
- Study of the Safety and Tolerability of AXA1125 and AXA1957 in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)NA · COMPLETED · started Dec 3, 2018ClinicalTrials.gov NCT04073368 · fetched Nov 12, 2026